Category
Page
Home - PM Group
Cell and Gene Therapy – Pharma's new frontier
Cell and Gene Therapy (CGT) is a rapidly evolving field. PM Group has wide ranging expertise in the design and development of CGT facilities.
Adaptability of facilities
Adaptability is key in this fast-changing area of Advanced Therapeutic Medicinal Products (ATMPs). Adaptable facilities allow for faster speed to market for autologous and allogeneic cell therapies, gene therapies and associated vector and plasmid production. Flexible, adaptable facilities can also support a changing mix of modalities and evolving process technologies.
Modular design
Modular, repeatable design facilitates a gradual introduction of ATMP manufacturing within existing facilities or sites. It can also enable future growth, accommodate changes in production volume and allow replication across multiple locations.
Logistics and robotics
Personalised medicines present unique and complex challenges. Manufacturers are trusted with the patient’s own cells. Smooth cell transit and robust tracking is crucial. The scale-out nature of Quality Control in these facilities is a further driver of logistics complexity. Lean laboratory design is a requirement for rapid transit of patient data to enable swift product release.
PM Group’s designs ensure speed, reliability and chain of identity throughout the facility and QC. We achieve this by integrating our architecture, process and advanced automation designs, ensuring a best in class solution.
Do you have a Cell and Gene Therapy project? Talk to our experts.